Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Neurokinin 3 Receptor Antagonism Rapidly Improves Vasomotor Symptoms With Sustained Duration of Action

Prague, Julia K.; Roberts, Rachel E.; Comninos, Alexander N.; Clarke, Sophie; Jayasena, Channa N.; Mohideen, Pharis; Lin, Vivian H.; Stern, Theresa P.; Panay, Nicholas; Hunter, Myra S.; Webber, Lorraine C.; Dhillo, Waljit S.

Obstetrical & Gynecological Survey: April 2019 - Volume 74 - Issue 4 - p 221–222
doi: 10.1097/OGX.0000000000000665

(Abstracted from Menopause 2018;25(8):862–869)

Approximately 70% of postmenopausal women experience vasomotor symptoms, and 10% describe these symptoms as intolerable. Conventional treatment of hot flashes (HFs) includes hormone therapy and other alternative treatments; however, these treatments have mixed responses, variable availability, and can be contraindicated in some women such as those with a history of breast cancer.

Department of Investigative Medicine, Imperial College London, London, United Kingdom (J.K.P., R.E.R., A.N.C., S.C., C.N.J., W.S.D.); Millendo Therapeutics, Inc, Ann Arbor (P.M., V.H.L.); TPS Pharmaceutical Consulting, Saline (T.P.S.), MI; Department of Gynaecology, Queen Charlotte's & Chelsea Hospital and Chelsea & Westminster Hospital (N.P.); Institute of Reproductive and Development Biology, Imperial College London (N.P.); Institute of Psychiatry, Psychology & Neuroscience, King's College London (M.S.H.), London; and Emerging Innovations Unit, Scientific Partnering and Alliances, IMED Biotech Unit, AstraZeneca, Cambridge (L.C.W.), United Kingdom

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.